Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-02-20

Clinical Trial Update: A Crossover Study of the Safety and Tolerability of Two Formulations of Adalimumab [Phase 2]

View source ↗

Summary

Phase 2 crossover trial evaluated the safety and tolerability of two formulations of adalimumab in rheumatoid arthritis; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ADALIMUMAB (ADALIMUMAB-AATY)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED | Results posted: 2014-02-20